Aarti Pharmalabs reported FY2026 revenue of ₹1,798 crore, but net profit fell to ₹176 crore from ₹257 crore in FY2025. This decline was due to a ₹33 crore forex loss and higher costs from new capacity ramp-up impacting profitability.
Aarti Pharmalabs FY26 Revenue at ₹1,798 Cr, PAT Falls to ₹176 Cr Amidst Margin Pressure
Standalone Revenue (FY2026): ₹1,798 crore Standalone PAT (FY2026): ₹176 crore Reader Takeaway: Revenue growth is steady, but temporary margin pressures impact near-term profitability. ## What just happened Aarti Pharmalabs Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a standalone revenue of ₹1,798 crore for the full fiscal year 2026. However, its standalone Profit After Tax (PAT) saw a decline, reaching ₹176 crore compared to ₹257 crore in the previous fiscal year (FY2025). ## Why this matters The decline in PAT, despite revenue growth, is a key concern for investors. Management attributed this to a net foreign exchange loss of ₹33 crore and increased operational costs associated with scaling up new manufacturing capacities. These costs have not yet been fully offset by corresponding revenue, leading to short-term margin pressure. ## The backstory The company is in a growth phase, investing in new capacities. The CDMO/CMO segment showed robust growth, up 32% year-on-year, with 54 active projects contributing ₹276 crore in FY2026 revenue. The Xanthine segment also remains a strong contributor, accounting for 43% of Q4 revenue. The API & Intermediates segment is expected to grow in FY2027. ## What changes now Management has maintained its guidance for 15% to 18% annual growth in revenue and EBITDA over the next three to four years. The focus will be on the effective ramp-up of new capacities at Atali and Tarapur. Investors will be watching the company's ability to translate these investments into revenue and improve profitability as the capacities become fully operational and cost efficiencies are realized. ## Risks to watch Key risks include continued margin pressure due to inflation in raw materials, energy, and logistics. The significant working capital requirements for large CDMO projects also pose a challenge. Additionally, forex volatility could impact future earnings. ## Peer comparison While specific peer comparisons were not detailed in the filing, Aarti Pharmalabs operates in the competitive pharmaceutical ingredients and contract manufacturing space. Companies in this sector often face similar challenges related to regulatory compliance, raw material costs, and global demand fluctuations. ## Context metrics (time-bound) * **Standalone Revenue FY2026:** ₹1,798 crore (vs. FY2025's ₹257 crore PAT implies substantial revenue growth). * **Standalone PAT FY2026:** ₹176 crore (down from ₹257 crore in FY2025). * **Q4 FY2026 Revenue:** ₹580 crore. * **Q4 FY2026 PAT:** ₹62 crore. * **CDMO/CMO Revenue FY2026:** ₹276 crore (up 32% YoY). * **Xanthine Revenue FY2026:** ₹792 crore. * **Forex Loss:** ₹33 crore (full year impact). * **Dividend:** Final dividend of ₹2 per share declared (₹3.50 total for the year). ## What to track next Investors should monitor the operational performance and revenue generation from the newly commissioned capacities. The company's ability to manage cost escalations and currency fluctuations, alongside progress in the CDMO pipeline, will be crucial for future earnings growth and margin recovery.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
